Clinical Trial

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent/metastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07497386
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
Enrollment 150 participants
Start Date 2026-04-28
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-11